New Leukemia Classification Controversey 2022

Returning guests Sanam Loghavi, MD, hematopathologist and molecular pathologist, University of Texas MD Anderson Center, and Aaron Goodman, MD, hematologist, University of California San Diego, break down the latest classification system updates in leukemia.
They begin by explaining what triggers a new classification and why it is needed, how soon clinicians should adopt it, and the relationship as well as differences between the ICC and WHO classification systems. Then, the experts go into the details of the changes that have been made to AML and MDS diagnoses and how these are likely to impact clinical trials, among other important points.
This is such a lively discussion with two amazing guests that care deeply about patient care. How are these two new classifications impacting patients and trials? a must listen.
Don't forget to subscribe, like, review, and refer your friends and colleagues to the "Healthcare Unfiltered" podcast.

[@kaelthuzad4640]

Thanks to all the brilliant scientists for this talk and for spreading the knowledge.
i have a question please : does the WHO/ICC 2022 update mean that we will need from now on, to be performing cytogenetics/molecular biology , searching for recurrent AML abnomalies , systematically on all bone marrow samples ?

[@ahmedalrajjal4820]

Thank you

[@vivianyin4285]

great video! Thank u!